查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854163

HIV臨床試驗市場按藥物類別、試驗階段、最終用戶、給藥途徑、分銷管道和患者年齡層分類－2025-2032年全球預測

HIV Clinical Trials Market by Drug Class, Trial Phase, End User, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，愛滋病臨床試驗市場規模將達到 21.9 億美元，複合年成長率為 7.43%。

關鍵市場統計數據
基準年2024年 12.3億美元
預計年份：2025年 13.3億美元
預測年份 2032 21.9億美元
複合年成長率 (%) 7.43%

本文簡要概述了現代愛滋病臨床試驗現狀，重點介紹了創新促進因素、營運限制以及相關人員的策略要務。

全球開發安全、有效且可及的愛滋病療法的努力已進入一個創新加速和務實調整的時期。抗病毒機制的科學進步、試驗設計的改進以及對以患者為中心的療效指標日益成長的關注，都與人們對營運效率和公平獲取的日益成長的期望相輔相成。同時，臨床試驗贊助者、臨床實驗和研究中心都面臨著不斷變化的監管要求和複雜的臨床實驗鏈，這需要他們做出相應的調整規劃。

本執行摘要旨在幫助決策者深入了解影響現代愛滋病臨床試驗的關鍵因素。它明確了核心的科學和營運促進因素，重點指出了可能擾亂研發進度的系統性風險，並為相關人員提供了增強專案韌性的實用方法。摘要整合了臨床、後勤和政策觀點，為領導者提供了清晰的觀點，以便他們在確保倫理和監管嚴謹性的同時，優先考慮投資、改善夥伴關係並加速轉化研究進程。

應將資源分配到哪些方面以改善研究人員的招募和留任？應如何預見和管理跨境營運摩擦？哪些共同研究模式最有可能在不損害安全性和資料完整性的前提下，縮短獲得可靠證據的時間？

科學突破、監管現代化和數位轉型如何重新定義愛滋病臨床試驗模式和營運重點

科學突破、數位轉型和政策演變正在重塑愛滋病臨床試驗。分子病毒學和新型藥物的進步正在拓展治療途徑，而適應性試驗設計和分散式管理模式也開始改變受試者的招募、監測和留存方式。這些轉變正在減少傳統的瓶頸，並創造機會更有效率地檢驗更具針對性的假設。同時，數位化終點、遠端監測平台和電子源資料擷取的應用，使得以患者為中心的持續性評估成為可能，並減輕了研究中心的負擔。

全球監管機構也展現出對創新方法的開放態度，尤其是在試驗設計中明確考慮風險緩解措施並實施嚴格的資料品管時。然而，這種監管開放性也帶來了對資料來源、設備檢驗和受試者保護的更高期望，因此需要儘早進行對話與合作。此外，官民合作關係和產學研聯盟的興起正在加速轉化研究，但也引發了關於資料共用、智慧財產權管理和利益公平分配等重要議題。

隨著這些變革力量的匯聚，相關人員必須平衡速度與嚴謹性、創新與可近性。務實地整合新技術，並輔以深思熟慮的相關人員參與和增強供應鏈韌性，將決定哪些專案能夠充分發揮其潛力，帶來意義深遠的臨床進展。

評估美國關稅及相關貿易政策轉變如何重塑愛滋病臨床試驗供應鏈、營運成本和國際合作動態。

近期美國關稅及相關貿易政策的調整對愛滋病臨床試驗生態系統產生了顯著的間接影響，主要體現在上游成本和物流格局的改變，而非直接改變科學典範。原料藥、專用實驗室設備和關鍵包裝組件的關稅可能延長採購前置作業時間，並推臨床實驗藥物生產和臨床供應鏈中的常規採購成本。因此，臨床試驗贊助者和製造外包生產商越來越重視雙重採購、庫存緩衝以及與報關行密切協調，以確保臨床實驗按時進行。

除了材料成本之外，關稅還會使支撐全球臨床試驗網路的跨國合作變得複雜。依賴進口診斷劑和低溫運輸的研究機構可能會面臨意想不到的短缺和海關延誤，如果不能積極應對，可能會擾亂檢體處理並損害資料完整性。此外，關稅帶來的成本壓力可能會加劇輔助服務的價格談判，導致一些申辦者重新評估實驗室服務的地理分佈、中心實驗室整合或更多地依賴區域供應商。

重要的是，關稅的影響與政策和營運應對措施密切相關，例如監管靈活性（用於檢驗替代供應商）、加快臨床用品進口授權，以及在申辦者和供應商之間分配風險的合約條款。展望未來，產業領導者應預見關稅波動將繼續影響供應計劃，並應納入基於情境的風險評估、加強供應商管治以及提高階到端物流可視性，以保護臨床項目免受不必要的干擾。

從細分市場的觀點主導，探討治療層級、臨床試驗階段、治療環境、給藥途徑、通路和患者年齡等因素如何相互作用，進而影響臨床試驗的策略選擇。

細分分析揭示了不同治療類別、臨床試驗階段、治療環境、給藥途徑、通路和患者族群的差異化策略意義。按藥物類別分類決定了治療研發的不同優先事項：整合酶鏈轉移抑制劑，例如比克替拉韋、多替拉韋、埃爾維特格拉韋和拉替拉韋，有助於簡化治療方案，但需要關注藥物交互作用和抗藥性監測。非核苷類逆轉錄酶抑制劑，例如依非韋倫、依曲韋林、奈韋拉平和利匹韋林，其安全性和中樞神經系統耐受性特徵需納入試驗設計；而核苷類逆轉錄酶抑制劑，例如恩曲他濱、拉米夫定、替諾福韋和齊多夫定，仍是骨幹策略的核心。蛋白酶抑制劑，例如阿扎那韋、達蘆那韋、福沙那韋和洛匹那韋，需要評估其代謝和依從性，這些因素會影響終點的選擇。

根據試驗階段的不同，重點也會有所變化：I期和IIa/IIb期側重於安全性和概念驗證，III期側重於更廣泛的療效和比較終點，而IV期則側重於真實世界安全性。臨床試驗的階段會影響樣本大小、操作複雜性和監測強度，進而影響研究中心的照護現場臨床實驗和全面監測，而研究機構，包括學術中心和合約研究組織，通常提供專業知識和密集的數據監測。

給藥途徑（注射、口服、經皮）的選擇會影響病患的接受度和供應鏈要求。注射劑需要低溫運輸和無菌配製能力，而口服方案則更著重於提高患者的依從性。分銷通路（醫院、線上和零售藥局，零售藥局又分為連鎖店和獨立藥局）的差異會影響配藥流程和臨床實驗後藥物取得計畫。最後，患者族群（成人、老年人、兒童）的差異也需要對安全性監測、知情同意流程和終點選擇進行調整，以確保臨床試驗能夠針對不同族群產生具有臨床意義的證據。

深入了解美洲、歐洲、中東和非洲以及亞太地區的區域營運和監管情況，為臨床實驗選址和執行策略提供基礎。

區域動態對研究設計、營運執行和監管參與有顯著影響。儘管美洲地區完善的研究基礎設施和成熟的法律規範使許多申辦方能夠迅速啟動試驗，但該地區內部的地域差異也要求對試驗中心進行仔細評估，以確保受試者俱有代表性並享有公平的試驗機會。北美臨床試驗中心通常引領臨床實驗創新，而拉丁美洲臨床試驗中心則在驗證真實世界療效和擴大受試者多樣性方面發揮關鍵作用。

歐洲、中東和非洲的監管環境各不相同，既有協調統一的努力，也有各地區特有的要求。在這一廣袤地區開展業務的申辦方必須權衡經驗豐富的學術中心和龐大的患者群帶來的優勢，以及倫理審查時間長短不一和行政流程繁瑣等問題。在許多司法管轄區，投資於能力建構、標準化資料擷取流程以及早期與監管機構對話已被證明對減少延誤和維持資料品質至關重要。

亞太地區擁有快速成長的臨床研究能力，並具備多樣化的報銷和監管途徑。該地區為加快患者招募和接觸多元化患者群體提供了機會，但成功與否取決於文化適應性強的招募策略、當地研究者的積極參與以及完善的供應鏈計劃，以應對進口和臨床實驗交付等問題。在所有地區，臨床實驗臨床實驗架構與當地臨床實驗實踐相契合、當地相關人員的積極參與以及對研究中心培訓和品質監管的投入，對於獲得完整且可推廣的證據至關重要。

提供有關主要贊助商、合作模式和服務供應商的資訊，這些因素共同塑造了愛滋病毒臨床開發領域的營運績效和轉化動力。

參與 HIV 臨床開發的公司的競爭格局包括成熟的製藥贊助商、專業的生技藥品開發商、合約研究和委外研發機構、學術聯盟以及專注於數據、物流和病人參與的服務供應商，而新興企業和生物技術創新者則提供專注於差異化作用機制和目標人群的利基提案主張。

從產業界與學術中心之間的策略聯盟到共用方案和數據的多方相關人員，共同研究模式正日益凸顯，成為分散風險和加速證據生成的重要途徑。委外研發機構和專業服務供應商在營運複雜的測試環節中發揮關鍵作用，例如長效注射劑的生產、低溫運輸管理和分散式測試環節。提供電子資料收集、遠端監控和可互通實驗室資訊系統等技術供應商對於確保資料完整性和合規性也日益重要。

在這個生態系統中，領導力取決於科學清晰度和卓越營運的整合。那些能夠將精準的機制假設與強力的研究中心管治、靈活的供應安排以及符合當地實際情況的招募策略相結合的機構，將更有能力開展高品質的臨床試驗，並獲得具有臨床意義的結果。

為贊助商和營運領導者提供可操作的建議，以增強 HIV 臨床試驗中的供應彈性、監管協調、參與者參與和共同研究模式。

產業領導者應優先採取一系列切實可行的措施，以增強韌性、加快證據產生並確保公平取得。首先，投資多元化的供應商網路和合約機制，以維持臨床實驗藥物和關鍵檢測試劑的持續供應。其次，精心整合分散式試驗要素，以減輕受試者負擔，同時保持嚴格的監控控制和有效的遠端資料收集。

第三，儘早並經常與監管機構和倫理委員會溝通，以就適應性設計、生物標記終點和安全監測框架達成一致。第四，制定符合當地實際情況且兼顧文化敏感性的招募和保留策略，尤其是在涉及多個地區和人群的臨床試驗中。第五，實施資料管治，以確保互通性、可追溯性和快速審核，從而滿足監管要求和已發布的標準。

最後，促進合作聯盟和官民合作關係，共用非競爭性數據和基礎設施，將降低小型開發人員的進入門檻，並加速比較效果研究。透過將這些措施納入專案規劃，領導者可以降低營運風險，最佳化資源分配，並提高試驗產生具有臨床實用性和普遍適用性結果的機率。

一種透明的三角調查方法，整合了訪談、文獻研究、營運案例研究和嚴​​格的檢驗，以確保測試資訊的可靠性。

本報告的分析是基於三角測量調查方法，該方法結合了對關鍵意見領袖的訪談、對同行評審文獻和官方監管文件的二手研究，以及對近期愛滋病臨床試驗計畫的案例研究。主要資訊來源包括對首席研究員、臨床實驗營運負責人、供應鏈管理人員和患者諮詢負責人的結構化訪談，以了解第一線挑戰和新興最佳實踐。二手資訊來源包括臨床實驗試驗報告、監管指導文件和方法學文獻，這些資料為研究設計、安全性監測和終點選擇提供了基礎。

所採用的分析框架包括風險映射（用於識別供應鏈脆弱性）、決策樹模型（用於選址）以及相關人員影響矩陣（用於確定緩解策略的優先順序）。檢驗步驟包括將訪談內容與已記錄的測試結果最後覆核，以及由外部專家進行迭代審查，以確保解釋的準確性。品管包括查找所有引用的監管意見，以及保留訪談記錄和綜合筆記的內部審核追蹤。

報告發布後，貿易政策和監管指導方針可能會發生變化。為減少這些局限性，本調查方法強調透明的假設、基於情境的分析，以及對實際觀察到的情況與專家預測的明確區分。

一項策略綜合，整合了營運要務、協作方法和以參與者為中心的設計，以指導有效的 HIV 臨床開發決策。

整合觀點、營運和觀點，觀點參與愛滋病臨床研發的機構提供一套連貫的優先事項。目前最迫切的挑戰是如何將創新的臨床試驗設計與務實的執行結合。應利用適應性和分散性要素來提高效率，同時確保有效的資料流和符合法規要求。同樣重要的是，鑑於供應檢體韌性和供應商管治對招募延遲和樣本處理品質的影響，必須將其視為試驗可行性不可或缺的一部分，而非事後考慮的因素。

從策略層面來看，申辦方應尋求整合產業界、學術界和專業服務供應商優勢的合作架構，以加速轉化研究進程並擴大受試者群體的多樣性。營運負責人必須投資於支援遠端監測、標準化實驗室操作和文化適應性招募的數位化和人力資源基礎設施。最後，與監管機構和社區相關人員保持持續溝通將有助於開發新的終點指標，並增強公眾對試驗結果的信心。

將科學抱負與營運嚴謹性相結合、預測並減輕供應和政策風險、並將參與者需求納入試驗設計的組織，將更有能力提供強力的、可操作的證據，從而推進愛滋病毒感染者的治療和獲得治療的機會。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將長效注射抗逆轉錄病毒療法納入常規愛滋病治療，以提高藥物依從性
  • 針對多種 HIV-1 譜系的廣譜中和抗體檢測技術取得進展，以提高其療效
  • 引入一種利用遠端醫療的去中心化臨床試驗模式，以提高愛滋病研究中病患的留存率
  • 開發一種雙效治療性疫苗，旨在增強愛滋病患者的免疫力並減少病毒庫大小。
  • 探索基於 CRISPR 的基因編輯方法作為早期 HIV 臨床試驗中潛在的功能性治癒手段
  • 運用真實世界數據分析來開發適應性試驗設計並最佳化愛滋病藥物開發平臺

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的愛滋病臨床試驗市場

  • 進入抑制劑
    • 恩夫韋地
    • 馬拉威羅克
  • 整合酶鏈轉移抑制劑
    • 比克替拉韋
    • 多替拉韋
    • 埃爾維特格拉維爾
    • 雷替拉韋
  • 非核苷類逆轉錄酶抑制劑
    • 依法韋侖
    • 依曲韋林
    • 奈韋拉平
    • 利匹韋林
  • 核苷類逆轉錄酶抑制劑
    • 恩曲他濱
    • 拉米夫定
    • 替諾福韋
    • 齊多夫定
  • 蛋白酶抑制劑
    • 阿扎那韋
    • 達蘆那韋
    • 福沙那韋
    • 洛匹那韋

9. 按試驗階段分類的愛滋病臨床試驗市場

  • 第一階段
  • 第二階段
    • 第二階段a
    • IIb期
  • 第三階段
  • 第四階段

第10章：以最終用戶分類的愛滋病臨床試驗市場

  • 診所
  • 醫院
  • 研究機構
    • 學術機構
    • 合約研究組織

第11章：按給藥途徑分類的愛滋病臨床試驗市場

  • 注射
  • 口服
  • 經皮

12. HIV臨床試驗市場按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥局
    • 連鎖藥局
    • 獨立藥房

13. 按病患年齡層別分類的 HIV 臨床試驗市場

  • 成人
  • 老年人
  • 孩子們

14. 按地區分類的愛滋病臨床試驗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：按組別分類的愛滋病臨床試驗市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國愛滋病臨床試驗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Gilead Sciences, Inc.
    • ViiV Healthcare Limited
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Roche Holding AG
    • Pfizer Inc.
    • AbbVie Inc.
    • Sanofi SA
    • Moderna, Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: MRR-7C50F273957B

The HIV Clinical Trials Market is projected to grow by USD 2.19 billion at a CAGR of 7.43% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.23 billion
Estimated Year [2025] USD 1.33 billion
Forecast Year [2032] USD 2.19 billion
CAGR (%) 7.43%

A concise framing of the contemporary HIV clinical trials landscape highlighting innovation drivers, operational constraints, and strategic imperatives for stakeholders

The global effort to develop safe, effective, and accessible HIV therapies has entered a period of intensified innovation and practical recalibration. Scientific advances in antiviral mechanisms, improvements in trial design, and an increasing emphasis on patient-centered outcomes have combined with heightened expectations for operational efficiency and equitable access. Simultaneously, sponsors, investigators, and trial sites face evolving regulatory expectations and supply-chain complexities that require adaptive planning.

This executive summary provides decision-makers with a focused synthesis of the forces shaping contemporary HIV clinical trials. It identifies core scientific and operational drivers, highlights systemic risks that can impede development timelines, and surfaces practical levers stakeholders can use to strengthen program resilience. By integrating clinical, logistical, and policy perspectives, the summary gives leaders a clear vantage point from which to prioritize investments, refine partnerships, and accelerate translational pipelines while maintaining ethical and regulatory rigor.

Throughout, the analysis emphasizes actionable clarity: where to allocate resources to improve recruitment and retention, how to anticipate and manage cross-border operational friction, and which collaborative models have demonstrated the greatest potential to shorten time to reliable evidence without compromising safety or data integrity.

How scientific breakthroughs, regulatory modernization, and digital transformation are collectively redefining HIV clinical trial paradigms and operational priorities

HIV clinical trials are being reshaped by a conjunction of scientific breakthroughs, digital transformation, and policy evolution. Advances in molecular virology and novel drug modalities have expanded the therapeutic toolkit, while adaptive trial designs and decentralized elements have begun to change how participants are recruited, monitored, and retained. These shifts reduce conventional bottlenecks and create opportunities to test more targeted hypotheses with greater efficiency. At the same time, the adoption of digital endpoints, remote monitoring platforms, and electronic source data capture is enabling more continuous, patient-centric assessments and reducing site burden.

Regulatory agencies worldwide are also signaling increased openness to innovative approaches, particularly when studies are designed with clear risk mitigation and robust data quality controls. This regulatory receptivity, however, comes with heightened expectations around data provenance, device validation, and participant protections, which require early dialog and alignment. Moreover, the emergence of public-private partnerships and academic-industry consortia is accelerating translational research while raising important questions about data sharing, IP stewardship, and equitable distribution of benefits.

As these transformative forces coalesce, stakeholders must balance speed with rigor, and innovation with access. Pragmatic integration of new technologies, coupled with deliberate stakeholder engagement and strengthened supply resilience, will determine which programs realize their potential to deliver meaningful clinical advances.

Assessing how United States tariff measures and related trade policy shifts are reshaping HIV clinical trial supply chains, operational costs, and international collaboration dynamics

Recent tariff measures implemented by the United States and related trade policy shifts have had a pronounced indirect effect on the HIV clinical trials ecosystem, primarily by altering upstream cost and logistics dynamics without directly changing scientific paradigms. Tariffs on active pharmaceutical ingredients, specialized laboratory equipment, and essential packaging components can increase procurement lead times and elevate routine sourcing costs for investigational product manufacturing and clinical supply chains. In turn, sponsors and contract manufacturers have increasingly prioritized dual sourcing, inventory buffering, and closer coordination with customs brokers to preserve study timelines.

Beyond material costs, tariffs can complicate cross-border collaborations that underpin global trial networks. Research sites that rely on imported diagnostic reagents or cold-chain logistics may experience episodic shortages or face unexpected customs delays, which can disrupt specimen handling and compromise data integrity if not proactively managed. Additionally, tariff-driven cost pressure can intensify negotiations around pricing for ancillary services, leading some sponsors to re-evaluate the geographic distribution of laboratory services, central lab consolidation, or greater reliance on regional suppliers.

Importantly, tariff effects intersect with policy and operational responses: regulatory flexibility for alternative supplier validation, accelerated import permits for clinical supplies, and contractual clauses that allocate risk among sponsors and providers. Looking ahead, industry leaders should anticipate that tariff volatility will remain a factor in supply planning and should incorporate scenario-based risk assessments, strengthened supplier governance, and enhanced visibility into end-to-end logistics to shield clinical programs from avoidable disruption.

Segmentation-driven perspectives on how therapeutic class, trial phase, care setting, administration route, distribution channel, and patient age intersect to shape strategic trial choices

Segmentation analysis reveals differentiated strategic implications across therapeutic categories, trial stages, care settings, administration routes, distribution channels, and patient demographics. When classified by drug class, therapeutic development priorities vary: Entry Inhibitors such as enfuvirtide and maraviroc focus on targeting initial viral entry mechanisms and often require parenteral administration strategies, whereas Integrase Strand Transfer Inhibitors including bictegravir, dolutegravir, elvitegravir, and raltegravir frequently underpin regimen simplification efforts and demand attention to drug-drug interactions and resistance surveillance. Non-Nucleoside Reverse Transcriptase Inhibitors like efavirenz, etravirine, nevirapine, and rilpivirine bring their own safety and CNS tolerability profiles to trial design, while Nucleoside Reverse Transcriptase Inhibitors-emtricitabine, lamivudine, tenofovir, and zidovudine-remain central to backbone strategies. Protease Inhibitors such as atazanavir, darunavir, fosamprenavir, and lopinavir require evaluation of metabolic and adherence considerations that influence endpoint selection.

By trial phase, the emphasis shifts from safety and proof-of-concept in Phase I and Phase IIa/IIb to broader efficacy and comparative endpoints in Phase III and real-world safety in Phase IV. Trial phase influences sample size, operational complexity, and monitoring intensity, which in turn affects site selection and patient engagement strategies. End-user segmentation underscores different operational models: clinics and hospitals deliver point-of-care recruitment and integrated monitoring, while research institutes, including academic centers and contract research organizations, often provide specialized expertise and centralized data oversight.

Route of administration considerations-injectable, oral, and transdermal-drive both patient acceptability and supply-chain requirements, with injectables requiring cold-chain or sterile compounding competencies and oral regimens emphasizing adherence support. Distribution channel nuances across hospital pharmacies, online pharmacies, and retail pharmacies, with retail further divided into chain and independent outlets, affect dispensing workflows and post-trial access planning. Finally, patient age groups-adult, geriatric, and pediatric-necessitate tailored safety monitoring, consent processes, and endpoint selection to ensure that trials generate clinically actionable evidence for each population segment.

Regional operational and regulatory insights across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform optimized trial site selection and execution strategies

Regional dynamics exert a strong influence on trial design, operational execution, and regulatory engagement. In the Americas, established research infrastructures and mature regulatory frameworks facilitate rapid study start-up for many sponsors, yet geographic diversity within the region necessitates careful site feasibility assessments to ensure representative enrollment and equitable access. Clinical sites in North America often lead in early-phase innovation, while sites across Latin America play a critical role in demonstrating real-world effectiveness and expanding participant diversity.

Europe, Middle East & Africa presents a heterogeneous regulatory landscape where harmonization initiatives coexist with localized requirements. Sponsors operating across this expanse must balance the advantages of experienced academic centers and large patient pools against variable ethics review timelines and administrative processes. In many jurisdictions, investment in capacity building, standardized data-capture practices, and early regulatory dialogue proves essential to mitigate delays and maintain data quality.

Asia-Pacific combines rapidly growing clinical research capacity with variable reimbursement and regulatory pathways. The region offers opportunities for accelerated enrollment and access to diverse patient populations, but success depends on culturally adapted recruitment strategies, local investigator engagement, and robust supply-chain planning to navigate importation and site provisioning. Across all regions, aligning trial architecture with local clinical practice, engaging community stakeholders, and investing in site training and quality oversight are pivotal to generating high-integrity, generalizable evidence.

Intelligence on influential sponsors, collaborative models, and service providers that are shaping operational excellence and translational momentum in HIV clinical development

The competitive landscape of organizations involved in HIV clinical development reflects a mix of established pharmaceutical sponsors, specialist biologics developers, contract research organizations, academic consortia, and service providers focused on data, logistics, and patient engagement. Established companies continue to leverage deep clinical experience and global development networks to advance large-scale registrational programs, while emerging players and biotech innovators concentrate on differentiated mechanisms of action and targeted populations to carve niche value propositions.

Collaborative models-ranging from strategic alliances between industry and academic centers to multi-stakeholder consortia that share protocols and pooled data-have become more prominent as a way to spread risk and accelerate evidence generation. Contract research organizations and specialty service providers play a critical role in operationalizing complex trial elements such as long-acting injectable manufacturing, cold-chain management, and decentralized trial components. Technology vendors that provide validated electronic data capture, remote monitoring, and interoperable laboratory information systems are increasingly integral to ensuring data integrity and regulatory compliance.

Leadership in this ecosystem depends on integrating scientific clarity with operational excellence. Organizations that combine precise mechanistic hypotheses with robust site governance, flexible supply arrangements, and community-informed recruitment strategies will be best positioned to execute high-quality trials that deliver clinically meaningful outcomes.

Actionable recommendations for sponsors and operational leaders to enhance supply resilience, regulatory alignment, participant engagement, and collaborative research models in HIV trials

Industry leaders should prioritize a set of pragmatic, actionable measures to increase resilience, accelerate evidence generation, and ensure equitable access. First, invest in diversified supplier networks and contractual mechanisms that preserve continuity of investigational product supply and critical laboratory reagents. Second, embed decentralized trial elements judiciously to reduce participant burden while maintaining rigorous monitoring controls and validated remote data capture.

Third, engage regulators and ethics committees early and often to align on adaptive designs, biomarker endpoints, and safety monitoring frameworks; proactive engagement reduces cycles and increases the likelihood of regulatory acceptance. Fourth, design recruitment and retention strategies that are community-informed and culturally sensitive, particularly when trials span multiple regions and demographic groups. Fifth, implement data governance practices that ensure interoperability, traceability, and rapid auditability to meet both regulatory expectations and publication standards.

Finally, cultivate collaborative consortia and public-private partnerships that share noncompetitive data and infrastructure, thereby lowering barriers to entry for smaller developers and accelerating comparative effectiveness research. By integrating these actions into program planning, leaders can reduce operational risk, optimize resource allocation, and increase the probability that trials generate clinically consequential and generalizable results.

A transparent, triangulated research methodology that integrates primary interviews, literature review, operational case studies, and rigorous validation to ensure reliable trial intelligence

The analysis underpinning this report draws on a triangulated research approach that combines primary interviews with key opinion leaders, secondary review of peer-reviewed literature and public regulatory documents, and operational case studies of recent HIV trial programs. Primary inputs include structured interviews with clinical investigators, trial operations leaders, supply-chain managers, and patient-advisory representatives to capture frontline challenges and emergent best practices. Secondary sources encompass clinical study reports, regulatory guidance documents, and methodological literature that inform trial design, safety monitoring, and endpoint selection.

Analytical frameworks employed include risk mapping for supply-chain vulnerability, decision-tree modeling for site selection, and stakeholder impact matrices to prioritize mitigation strategies. Validation steps incorporated cross-checks between interview insights and documented trial outcomes, as well as iterative reviews with external subject matter experts to ensure interpretive accuracy. Quality controls comprised source verification for all cited regulatory positions and internal audit trails for interview transcripts and synthesis notes.

Limitations are acknowledged, including the dynamic nature of trade policy and regulatory guidance, which may evolve after the report's compilation. To mitigate these constraints, the methodology emphasizes transparent assumptions, scenario-based analyses, and clear delineation between observed practice and expert projection, thereby enabling readers to adapt the findings to their specific operational contexts.

A strategic synthesis that integrates operational imperatives, collaborative approaches, and participant-centered design to guide effective HIV clinical development decisions

Bringing together scientific, operational, and policy perspectives yields a coherent set of priorities for organizations engaged in HIV clinical development. The most immediate imperative is to harmonize innovative trial design with pragmatic execution: leverage adaptive and decentralized elements to increase efficiency while ensuring validated data flows and regulatory acceptability. Equally important is treating supply-chain resilience and supplier governance as integral components of trial feasibility rather than as afterthoughts, given their demonstrated capacity to delay enrollment and compromise specimen handling.

Strategically, sponsors should pursue collaborative architectures that combine the strengths of industry, academia, and specialized service providers to accelerate translational pathways and broaden access to diverse participant cohorts. Operational leaders must invest in digital and human infrastructure that supports remote monitoring, standardized laboratory practices, and culturally tailored recruitment. Finally, sustained engagement with regulators and community stakeholders will smooth the path for novel endpoints and increase public trust in trial results.

Taken together, these imperatives set a practical agenda: integrate scientific ambition with operational rigor, anticipate and mitigate supply and policy risks, and center participant needs in study design. Organizations that execute along these lines will be better positioned to deliver robust, actionable evidence that advances therapy and access for people living with HIV.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of long-acting injectable antiretroviral therapies into routine HIV management to improve adherence
  • 5.2. Advancements in broadly neutralizing antibody trials targeting diverse HIV-1 clades for broader efficacy
  • 5.3. Implementation of decentralized clinical trial models leveraging telemedicine for enhanced patient retention in HIV studies
  • 5.4. Development of dual-acting therapeutic vaccines aiming to both boost immunity and reduce reservoir size in HIV patients
  • 5.5. Exploration of CRISPR-based gene editing approaches for potential functional cure in early-phase HIV clinical trials
  • 5.6. Adoption of real-world data analytics to inform adaptive trial designs and optimize HIV drug development pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV Clinical Trials Market, by Drug Class

  • 8.1. Entry Inhibitors
    • 8.1.1. Enfuvirtide
    • 8.1.2. Maraviroc
  • 8.2. Integrase Strand Transfer Inhibitors
    • 8.2.1. Bictegravir
    • 8.2.2. Dolutegravir
    • 8.2.3. Elvitegravir
    • 8.2.4. Raltegravir
  • 8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 8.3.1. Efavirenz
    • 8.3.2. Etravirine
    • 8.3.3. Nevirapine
    • 8.3.4. Rilpivirine
  • 8.4. Nucleoside Reverse Transcriptase Inhibitors
    • 8.4.1. Emtricitabine
    • 8.4.2. Lamivudine
    • 8.4.3. Tenofovir
    • 8.4.4. Zidovudine
  • 8.5. Protease Inhibitors
    • 8.5.1. Atazanavir
    • 8.5.2. Darunavir
    • 8.5.3. Fosamprenavir
    • 8.5.4. Lopinavir

9. HIV Clinical Trials Market, by Trial Phase

  • 9.1. Phase I
  • 9.2. Phase II
    • 9.2.1. Phase IIa
    • 9.2.2. Phase IIb
  • 9.3. Phase III
  • 9.4. Phase IV

10. HIV Clinical Trials Market, by End User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Research Institutes
    • 10.3.1. Academic Institutes
    • 10.3.2. Contract Research Organizations

11. HIV Clinical Trials Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
  • 11.3. Transdermal

12. HIV Clinical Trials Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. HIV Clinical Trials Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. HIV Clinical Trials Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. HIV Clinical Trials Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. HIV Clinical Trials Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Gilead Sciences, Inc.
    • 17.3.2. ViiV Healthcare Limited
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Johnson & Johnson
    • 17.3.5. Roche Holding AG
    • 17.3.6. Pfizer Inc.
    • 17.3.7. AbbVie Inc.
    • 17.3.8. Sanofi S.A.
    • 17.3.9. Moderna, Inc.
    • 17.3.10. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2025-203